New 'Tumor-Busting' peptide tested in advanced cancer patients
NCT ID NCT04260529
Summary
This early-stage trial tested a new experimental drug called CyPep-1, which is injected directly into tumors. The main goals were to see if it was safe and to find the right dose, both by itself and when combined with an existing immunotherapy drug (pembrolizumab). The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments, to see if the new approach could help control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EMC
Rotterdam, Netherlands
-
Institue Curie
Paris, France
-
Institute Gustave Roussy
Villejuif, France
-
LUMC
Leiden, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
START
Madrid, Spain
-
UMCU
Utrecht, Netherlands
-
Vall d'Hebron (VHIO)
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.